With 6 observations
Zydus Lifesciences announced that the USFDA conducted a surveillance inspection at the group's API Unit, located at Dabhasa in Gujarat. The inspection was conducted from April 21st to 25th, 2025.The inspection concluded with 6 observations and none of them were related to Data Integrity. The company is confident to address the observations expeditiously.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
